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MicroRNAs (miRNAs) are small RNA molecules with important gene regulatory roles 
in normal and pathophysiological cellular processes. Burkitt lymphoma (BL) is a 
MYC-driven lymphoma of germinal center B (GC-B) cell origin. To gain further 
knowledge on the role of miRNAs in the pathogenesis of BL, we performed small RNA 
sequencing in BL cell lines and normal GC-B cells. This revealed 26 miRNAs with 
significantly different expression levels. For five miRNAs, the differential expression 
pattern was confirmed in BL cell lines and primary tissues compared to GC-B cells. 
MiR-378a-3p was upregulated in BL and its inhibition reduced the growth of multiple 
BL cell lines. RNA immunoprecipitation of Argonaute 2 followed by microarray 
analysis (Ago2-RIP-Chip) upon inhibition and ectopic overexpression of miR-378a-3p 
revealed 63 and 20 putative miR-378a-3p targets, respectively. Effective targeting by 
miR-378a-3p was confirmed by luciferase reporter assays for MNT, FOXP1, IRAK4, 
and lncRNA JPX, all of which have been implicated in proliferation and cancer. In 
summary, we identified miR-378a-3p as a miRNA with an oncogenic role in BL and 
identified four novel miR-378a-3p target genes, i.e. MNT, FOXP1, IRAK4, and JPX.  
Keywords: Burkitt lymphoma; miR-378a-3p; cell growth; microRNA 
Introduction 
Burkitt lymphoma (BL) is one of the fastest growing human tumors with a cell doubling 
time of about 24 hours. BL mainly affects children and young adults but can also occur 
at later age [1]. The tumor cells are derived from germinal center B (GC-B) cells and 
usually carry the hallmark translocation involving MYC and the immunoglobulin heavy 
or light chain loci which results in high expression of MYC [2, 3].  
MicroRNAs (miRNAs) are a class of short non-coding RNAs of about 22 nucleotides. 
They modulate gene expression at the post-transcriptional level by translational 
inhibition or by inducing mRNA degradation [4, 5]. MiRNAs regulate a wide range of 
cellular processes, including cell cycle, proliferation, and apoptosis and are important 
determinants of B-cell development and maturation [6]. A widespread deregulation of 
miRNA expression has been observed in all B-cell lymphoma subtypes [7]. 
We and others have identified distinct miRNA expression patterns in BL and 
demonstrated the central role of MYC in regulating miRNA levels [8-12]. Functional 
studies showed crucial roles for the miR-17~92 cluster, miR-28, miR-150, and 
miR-155 as either oncogenic or tumor suppressor miRNAs in the pathogenesis of BL 
[9, 13-19]. Still, the role of most of the deregulated miRNAs in BL remains to be 
explored. 
MYC-induced miR-378a-3p is essential for BL growth 
67 
 
In this study we carried out small RNA-sequencing in BL cell lines and normal GC-B 
cells and subsequently focused on downstream functional experiments for 
miR-378a-3p. We show for the first time that this miRNA is upregulated in BL and 
confirmed its regulation by MYC. Further analysis indicated that miR-378a-3p is 
essential for growth of BL cells. Genome wide target gene identification revealed four 
novel targets of miR-378a-3p, including MNT, FOXP1, IRAK4 and JPX, with known 
functions related to cell growth. 
Results 
MiRNA expression profiling in BL and GC-B cells 
An overview of the total number of reads and percentages of mapped reads per 
sample is given in Table S1. The top-10 most abundantly expressed miRNAs 
accounted for 73% of all reads in BL and for 71% in GC-B cells (total GC-B cells 
sorted based on a +IgD-CD38+ or IgD-CD138-CD3-CD10+ phenotype). Seven of the 
top-10 most abundantly expressed miRNAs were shared between BL and GC-B cells 
(Figure 1A). Twenty-six miRNAs were significantly differentially expressed between 
BL and GC-B cells, including eight miRNAs upregulated in BL and 18 downregulated 
(Figure 1B). qRT-PCR validation on the same set of samples confirmed differential 
expression for six out of eight selected miRNAs (Figure 1C and Figure S1). Of the six 
validated miRNAs, miR-378a-3p levels were increased in BL relative to GC-B cells, 
while expression levels of miR-28-5p, miR-155-5p, miR-363-3p, miR-221-3p, and 
miR-222-3p were decreased. Further expression analysis in primary BL tissue 
samples and GC-B cells confirmed the differential expression for five of the six 
miRNAs, excluding miR-221-3p (Figure 1D).  
MYC-induced miR-378a-3p controls BL cell growth 
We selected miR-378a-3p for further functional analysis, because it was the only 
significantly upregulated miRNA with a high expression level in BL. Previous studies 
demonstrated that miR-378a-3p is induced by MYC in human mammary epithelial 
cells [20]. We assessed the regulatory role of MYC in B cells using the P493-6 B-cell 
model that has a tetracycline-repressible MYC allele [21]. Our results showed that this 
miRNA is also induced by MYC in B cells (Figure 2A). 
To explore the role of miR-378a-3p in growth of BL cells, we inhibited miR-378a-3p 
using a lentiviral miRNA inhibition construct (mZip-378a-3p) in 4 BL cell lines and 
followed cell growth in a GFP competition assay. Compared to the negative control 
(mZip-SCR), a significant decrease in the number of GFP-positive cells was observed 
in three (ST486, CA46, and DG75) out of four BL cell lines (Figure 2B). No relation 
was observed between the reduction in the percentage of GFP+ cells and the level of 
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miR-378a-3p expression (Figure S2). Together, our data indicate that inhibition of 
miR-378a-3p is disadvantageous for BL cells, suggesting miR-378a-3p is 
indispensable for growth of BL cells. 
Overexpression of miR-378a in ST486 using a lentiviral miRNA overexpression 
construct (pCDH-378a) resulted in a ~47-fold increase in miR-378a-3p level. In a GFP 
competition assay miR-378a overexpression had no effects on cell growth, probably 
due to the already high endogenous levels (data not shown). 
 
Figure 1. Deregulated expression patterns of miRNAs in BL compared to GC-B cells. (A) 
Overview of the top-10 most abundantly expressed miRNAs in Burkitt lymphoma (BL) and normal 
germinal center B (GC-B) cells as determined by small RNA-sequencing. Asterisks indicate miRNAs 
present in both the top-10 of BL and GC-B cells. (B) Heatmap of miRNAs significantly differentially 
expressed between BL and GC-B cells. (C) qRT-PCR validation results for 6 of the 8 tested miRNAs 
with significantly differential expression between BL cell lines and GC-B cells. MiRNA expression levels 
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were normalized to RNU44. (D) The differential expression pattern was confirmed for 5 of the 6 tested 
miRNAs when BL tissues and GC-B cells were compared. MiRNA expression levels were normalized to 
RNU49. Significant differences were calculated using unpaired T-test. *P < 0.05, **P < 0.01, and ***P < 
0.001. 
 
Figure 2. MYC-induced miR-378a-3p is essential for BL cell growth. (A) Levels of MYC and 
miR-378a-3p in tetracycline treated (“-”, MYC-off) and non-treated (“+”, MYC-on) P493-6 B-cells. MYC 
levels were normalized to RPII. MiRNA levels were normalized to RNU44. (B) Green fluorescent protein 
(GFP) growth competition assay upon miR-378a-3p inhibition in 4 Burkitt lymphoma (BL) cell lines. The 
miR-378a inhibitor (mZip-378a-3p) and the scrambled control (mZip-SCR) were stably transduced in 
BL cells using a lentiviral vector, which co-expresses GFP. The GFP percentage was measured for 22 
days, and the GFP percentage at the first day of measurement (day 4) was set to 100%. All assays 
were performed in triplicate. Significant differences were calculated using a mixed model analysis. ***P 
< 0.001 and ****P < 0.0001. 
Identification of miR-378a-3p targets 
To identify miR-378a-3p target genes, we performed Ago2-RIP-Chip upon 
miR-378a-3p inhibition and overexpression in ST486 cells (Figure S3A and B). 
Efficient pulldown of Ago2-containing RISC and miRNAs was confirmed by qRT-PCR 
for miR-378a-3p and the unrelated highly expressed miR-181a-5p (Figure S3C and D) 
and by western blot for Ago2 protein (Figure S3E and S4). The number of Ago2-IP 
enriched probes was similar in all 4 conditions, ranging between 6.3%-9.8% of the 
consistently expressed probes (Table 1).  
A total of 22 probes corresponding to 20 genes showed a ≥ 2-fold increased 
IP-enrichment upon miR-378a overexpression compared to empty vector control 
infected cells (Figure 3A and Table 2). Nine of the 20 genes (45%) had at least one 
putative miR-378a-3p binding site (7mer-A1, 7mer-m8, or/and 8mer). Six of them i.e. 
MNT, HSPB1, IRAK4, CCNK, CDKN2A, and RNF34, had a gene ontology (GO) term 
related to cell growth, apoptosis, and/or cell cycle. Upon miR-378a-3p inhibition, 74 
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probes, corresponding to 63 genes showed a ≥ 2-fold decreased IP-enrichment 
compared to the negative control infected cells (Figure 3B and Table 3). Nineteen of 
these 63 genes (30%) contained at least one putative miR-378a-3p binding site, 
including CISH, BCR, TUBA1C, SMARCA4, and FOXP1 with a GO term related to 
cell growth, apoptosis, or cell cycle. One of the target genes, i.e. MYCBP, was 
identified with both experimental setups.  
Table 1. Number of genes in the miRNA targetome upon miR-378a-3p overexpression 
(pCDH) and inhibition (mZip) 
IP/T  
ratio 
pCDH (n=9,233)   mZip (n=8,944) 
EV 378a 378a/EV 
 
SCR mZip-378a-3p SCR/mZip-378a-3p 
≥ 2 611 586 20 
 
741 878 63 
≥ 4 117 117 2 
 
171 196 4 
≥ 8 25 18 0   53 34 0 
EV = pCDH-EV, 378a = pCDH-378a, SCR = mZip-SCR. 
 
Table 2. Identified targets of miR-378a-3p upon overexpression 
Gene Transcript ID 
IP/T ratio   miR-378a-3p binding site  Growth-related  
GO EV* 378a FC 
 
5'UTR CDS 3'UTR 





CDKN2A ENST00000304494 1.0 4.0 4.0 
    
yes 
JPX ENST00000415215 1.5 5.8 3.9 
   
8m** 
 
PLGRKT ENST00000223864 1.0 3.0 3.0 
 
8m 
   
TMEM245 ENST00000374586 1.0 2.9 2.9 
   
7m8/8m 
 
TOMM6 ENST00000398884 1.5 4.1 2.7 
     
CDK1 ENST00000395284 1.0 2.6 2.6 
    
yes 
FAM117A ENST00000240364 1.4 3.6 2.6 
     
WDR83OS ENST00000596731 1.3 3.2 2.5 
 
7m8 
   





MYCBP ENST00000397572 2.3 5.4 2.3 
   
7mA1 
 
RNF34 ENST00000392465 1.3 3.0 2.3 
    
yes 
UBC ENST00000339647 1.0 2.3 2.3 
    
yes 
POP4 ENST00000585603 1.0 2.3 2.3 
     
MNT ENST00000174618 1.2 2.7 2.3 
  
7m8 7mA1 yes 





INAFM1 ENST00000552360 1.3 2.8 2.2 
     
PCNA ENST00000379160 1.0 2.1 2.1 
    
yes 
SP100 ENST00000264052 1.2 2.5 2.1 
     
RPP25L ENST00000297613 1.2 2.4 2.0 
     
*IP/T ratios in pCDH-EV (EV) were set to 1.0 in case the ratios were < 1.0.  
**The binding site in the noncoding RNA has been listed in the 3’-UTR column. 
7mA1 = 7mer-A1, 7m8 = 7mer-m8, 8m = 8mer, FC = fold change, and 378a = pCDH-378a, IP = 
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Table 3. Identified targets of miR-378a-3p upon inhibition 
Gene Transcript ID 
IP/T ratio   miR-378a-3p binding site 
Growth-related  
GO 
mZip-378a-3p* SCR FC   5'UTR CDS 3'UTR  
DYNLRB1 ENST00000357156 1.0 6.4 6.4 
     
VPS18 ENST00000220509 8.5 43.4 5.1 
     
NAPA-AS1 ENST00000594367 1.2 5.2 4.3 
   
7mA1** 
 
C11orf95 ENST00000433688 1.0 4.2 4.2 
     
HOMEZ ENST00000357460 1.2 4.3 3.5 
     
TMEM79 ENST00000405535 1.7 5.7 3.4 
     









ATP6V0C ENST00000330398 1.0 3.1 3.1 
     
CISH ENST00000348721 2.1 6.6 3.1 
   
8m yes 
lnc-FOXB1-8 lnc-FOXB1-8:1 1.0 3.3 3.1 
     
MT1B ENST00000334346 1.1 3.5 3.1 
    
yes 
lnc-EGLN1-1 lnc-EGLN1-1:6 1.0 2.9 2.9 
     
NELFA ENST00000382882 1.0 3.0 2.9 
     
BCR ENST00000305877 1.0 2.8 2.8 
  
7m8 7m8 yes 
MT1L ENST00000565768 1.2 3.2 2.8 
     




TRAF3IP2-AS1 ENST00000525151 1.0 2.7 2.7 
     
C22orf39 ENST00000611555 1.0 2.6 2.6 
     
KRTCAP2 ENST00000295682 1.6 4.1 2.6 
     
LINC01122 ENST00000427421 11.2 29 2.6 
   
7mA1** 
 
ACTG1P20 ENSG00000241547 1.3 3.2 2.5 
     
lnc-KRTAP5-10-1 lnc-KRTAP5-10-1:1 1.5 3.5 2.4 
   
7m8** 
 
MT1E ENST00000306061 1.1 2.8 2.4 
    
yes 
NUDT19 ENST00000397061 1.0 2.5 2.4 
   
7mA1 
 
PRDX4 ENST00000379341 1.0 2.4 2.4 
    
yes 
TMEM258 ENST00000537328 1.1 2.6 2.4 
     




BTG3 ENST00000629582 1.6 3.7 2.3 
    
yes 
EVI5L ENST00000270530 1.3 3.0 2.3 
     
LINC01534 ENST00000433232 1.0 2.3 2.3 
     
lnc-ADA-1 lnc-ADA-1:2 1.0 2.3 2.3 
     
lnc-ZNF431-4 lnc-ZNF431-4:1 1.1 2.6 2.3 
     
MT1A ENST00000290705 2.5 5.6 2.3 
    
yes 
CSRP2 ENST00000311083 2.7 5.9 2.2 
     
FYCO1 ENST00000296137 1.0 2.2 2.2 
   
7m8 
 
HYAL3 ENST00000336307 2.0 4.3 2.2 
     
KCNQ1 ENST00000632153 1.0 2.2 2.2 
     
lnc-RP11-158I9.5.1-2 TCONS_00019776 1.5 3.3 2.2 
     




PRSS36 ENST00000268281 1.4 2.8 2.2 
     









TOLLIP ENST00000317204 1.3 2.8 2.2 
   
7mA1 
 
ARF4 ENST00000303436 1.0 2.1 2.1 
    
yes 
ATG4D ENST00000309469 1.4 2.8 2.1 
    
yes 
CSE1L ENST00000262982 1.2 2.5 2.1 
    
yes 
lnc-PCF11-1 lnc-PCF11-1:12 1.5 3.2 2.1 
     
MARS ENST00000262027 1.7 3.6 2.1 
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Gene Transcript ID 
IP/T ratio   miR-378a-3p binding site 
Growth-related  
GO 
mZip-378a-3p* SCR FC   5'UTR CDS 3'UTR  
NANS ENST00000210444 1.0 2.1 2.1 
     
ORMDL2 ENST00000243045 1.1 2.3 2.1 
     




PGM2L1 ENST00000298198 1.8 3.7 2.1 
     
PTPN23 ENST00000265562 1.5 3.1 2.1 
     
TSACC ENST00000368255 1.5 3.1 2.1 
     





XLOC_l2_013031 TCONS_l2_00024809 6.5 13.7 2.1 
     
C15orf61 ENST00000342683 1.3 2.6 2.0 
   
8m 
 
LAT ENST00000360872 1.0 2.0 2.0 
     
LOC101929494 N/A 1.6 3.2 2.0 
     
MYCBP ENST00000397572 1.5 3.1 2.0 
   
7mA1 
 
NDRG4 ENST00000394279 1.1 2.2 2.0 
    
yes 
TUBE1 ENST00000368662 1.1 2.2 2.0 
    
yes 
*IP/T ratios in mZip-378a-3p were set to 1.0 if < 1.0.  
**Binding sites on noncoding RNAs have been listed in 3’-UTR column. 
7mA1 = 7mer-A1, 7m8 = 7mer-m8, 8m = 8mer, FC = fold change, SCR = mZip-SCR, and N/A = not 
available, IP = Ago2-immunoprecipitation fraction, T = Total fraction. 
Validation of miR-378a-3p targets by luciferase reporter assay  
For further analysis, we selected MYCBP that was identified in both approaches and 6 
candidates that had at least one 7mer-A1, 7mer-m8, or an 8mer and a GO term 
related to cell growth, apoptosis, or/and cell cycle (CISH, BCR, TUBA1C, FOXP1, 
MNT, and IRAK4). We also included the lncRNA JPX, as it showed a strong 
enrichment upon miR-378a-3p overexpression and contained an 8-mer seed binding 
site (Figure 3C). 
To confirm targeting of the 8 selected genes by miR-378a-3p, we carried out 
luciferase reporter assays for the 10 putative miR-378a-3p binding sites in ST486 and 
DG75. This revealed a strong reduction in the Renilla/Firefly ratio for four of the 
miR-378a-3p binding sites in four genes (IRAK4, FOXP1 (site 1), MNT, and JPX) 
(Figure S5). To further confirm specific binding by miR-378a-3p we generated 
constructs with mutations in these four miR-378a-3p binding sites. For IRAK4 (trend), 
FOXP1 and MNT (both significant) wildtype binding sites showed lower Renilla/Firefly 
ratios compared to the mutated binding sites (black bars in Figure 3D), indicating 
binding of endogenous miR-378a-3p to these sequences. Upon miR-378a-3p 
overexpression a significantly reduced Renilla/Firefly ratio was observed for the 
wildtype, but not to the mutated target sites confirming efficient and specific targeting 
(Figure 3D). Taking together, these results confirmed targeting of IRAK4, FOXP1, 
MNT, and the lncRNA JPX by miR-378a-3p. 
 




Figure 3. Identification and validation of miR-378a-3p targets. MiR-378a-3p targets identified by 
Ago2-RIP-Chip upon (A) miR-378a overexpression relative to empty vector (EV) and (B) scrambled 
vector relative to miR-378a-3p inhibition (SCR/mZip-378a). Black bars in panels A and B indicate genes 
with miR-378a-3p seed binding sites. (C) Schematic representations of the 8 genes selected for 
luciferase reporter assay validation. Black boxes indicate positions of the open reading frames (ORF). 
Positions and types of miR-378a-3p binding sites are indicated relative to the ORF. * this binding site 
was not tested. (D) Luciferase reporter assay results upon co-transfection of ST486 and DG75 cells 
with the Psi-check-2 construct containing the wildtype (WT) or mutated (MUT) miR-378a-3p binding 
sites from the selected genes and either miR-378a-3p mimic or a negative control mimic. Significant 
differences were calculated using a paired t-test. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 




In this study, we identified 26 miRNAs differentially expressed in BL cell lines 
compared to GC-B cells. For five of the miRNAs, deregulated expression levels were 
confirmed in both BL cell lines and primary tissues. Among them, miR-378a-3p is 
MYC-induced, highly abundant (top-10 within BL) and overexpressed in BL compared 
to GC-B cells. Inhibition of miR-378a-3p showed a negative effect on BL cell growth. 
In a genome-wide Ago2-RIP-Chip analysis, 20 and 63 genes were identified as the 
potential targets of miR-378a-3p upon miR-378a-3p overexpression and inhibition, 
respectively. Four genes i.e. MNT, FOXP1, IRAK4, and the lncRNA JPX were 
confirmed as novel targets of miR-378a-3p in BL. 
Six of the 26 identified differentially expressed miRNAs were reported to be 
deregulated in BL by Oduor et al. in a previous study [8]. These six included 
miR-155-5p, miR-221-3p, miR-222-3p, and miR-28-5p which we have validated by 
qRT-PCR in BL cell lines and tissue samples. Nine additional miRNAs were proven to 
be differentially expressed in BL compared to other B-cell lymphomas [9-12, 20]. Thus, 
our small RNA sequencing data confirmed some of the previously identified 
deregulated miRNAs in BL. Moreover, we showed for the first time that miR-378a-3p 
is a MYC-induced and significantly upregulated miRNA in BL. Since the role of 
miR-378a-3p in BL was not studied before, we focused on this miRNA for further 
functional analysis. 
Inhibition of miR-378a-3p resulted in a strong reduction of BL cell growth, suggesting 
a possible oncogenic role of miR-378a-3p in BL. The effect on growth upon 
miR-378a-3p was most pronounced in ST486. DG75 and CA46 showed intermediate 
phenotypes while no significant effect was observed in Ramos. There was no obvious 
relation between endogenous miR-378a-3p levels and the decrease in the percentage 
of GFP+ cells upon miR-378a-3p inhibition. Given the complex interactions between 
miRNAs and target genes, i.e. multiple targets per miRNA and multiple miRNAs per 
target, the differences in the observed phenotypes might be related to endogenous 
levels of either other miRNAs or target genes. Previous studies have shown opposite 
roles of miR-378a-3p in different cancer types. MiR-378a-3p was reported to inhibit 
growth or promote apoptosis and thus act as a tumor suppressor in colorectal cancer, 
lung cancer, ovarian cancer, prostate cancer and rhabdomyosarcoma [22-26]. In 
contrast, and in line with our findings, miR-378a-3p was shown to promote 
proliferation and reduce apoptosis in gastric cancer, nasopharyngeal carcinoma, 
colorectal cancer, and acute myeloid leukemia [27-30]. 
Using an unbiased genome-wide experimental approach we identified 83 putative 
miR-378a-3p target genes. Luciferase reporter assays confirmed targeting of 4 out of 
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8 selected genes i.e. protein coding genes MNT, IRAK4, FOXP1, and the lncRNA 
JPX. 
Previous studies showed a dual role of MNT in tumorigenesis. On the one hand, MNT 
was reported as a facilitator of MYC-driven T-cell proliferation and survival [31]. In line 
with this, a study in Eμ-MYC mice showed that reduced MNT levels reduced 
tumorigenesis [32], suggesting that MNT is indispensable for MYC-driven 
oncogenesis. However, in most studies MNT acted as a tumor suppressor and was a 
functional antagonist of MYC by repressing its activities related to cell cycle, 
proliferation, and apoptosis [33, 34]. Loss of MNT in mouse embryonic fibroblasts 
(MEFs) phenocopied the effect of MYC overexpression [35-37]. These findings are in 
line with our results and suggest that high levels of miR-378a-3p could promote BL 
tumorigenesis by reducing MNT levels and thereby enabling MYC to execute its 
oncogenic effects in BL. 
IL-1 receptor–associated kinase 4 (IRAK4) plays an essential role in the Toll-like 
receptor (TLR) pathway [38,39], which mediates inflammatory signals in B cells and 
causes activation of NF-κB. The TLR pathway is hyperactive in mantle cell lymphoma 
(MCL) and diffuse large B-cell lymphoma (DLBCL), and activation of NF-κB promotes 
B-cell survival and proliferation [40-42]. Depletion of IRAK4 showed a negative effect 
on NF-κB activity and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway, 
reducing survival of DLBCL cells [43,44]. Despite the pro-survival role of NF-κB in 
DLBCL, activation of NF-κB has been reported to be disadvantageous in MYC 
positive BL consistent with our data and supporting a role of miR-378a-3p-dependent 
repression of IRAK4 to limit activation of NF-κB [45,46]. 
FOXP1 as a member of the forkhead box (Fox) transcription factor family plays critical 
roles in organ development, cell division, survival, and metabolism in multiple tissues 
and in particular in the immune system [47,48]. It is a regulator of early B-cell 
development and is associated with expression of B-lineage genes [49]. FOXP1 
overexpression has been correlated with poor prognosis in follicular lymphoma (FL) 
and diffuse large B-cell lymphoma (DLBCL) [50-53], and reported to promote cell 
proliferation, cell cycle, and/or inhibit apoptosis of cervical cancer, myeloma, and 
glioma cells [54-56], indicating a pro-tumorigenic role. In contrast and more in line with 
our work, FOXP1 was described to have tumor suppressor like functions in lung and 
bladder cancer [57]. Interestingly FOXP1 expression is downregulated during the 
normal GC reaction and FOXP1 levels in BL are lower than in other B-cell lymphomas, 
comparable to GC-B cells [58,59]. Thus, the overexpression of miR-378a-3p may 
contribute to maintain low FOXP1 levels in BL. The potential relevance of low FOXP1 
is further supported by the finding that aberrant expression of FOXP1 cooperates with 
(constitutive) NF-κB activity [60] which might be disadvantageous for the survival of 
BL. 
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The long non-coding RNA JPX is an activator of XIST and acts as a molecular switch 
for X chromosome inactivation [61]. JPX was reported to act as an oncogene in 
ovarian cancer and non-small-cell lung cancer by promoting cell proliferation, invasion, 
and migration [62,63]. In hepatocellular carcinoma, JPX-dependent induction of XIST 
suppresses hepatocellular carcinoma progression by binding to the miR-155-5p 
oncomiR [64]. Current studies on JPX are limited and its potential role in BL remains 
unclear.  
In summary, we identified 26 differentially expressed miRNAs. We confirmed the 
differential and high expression of miR-378a-3p in BL and showed a significant 
negative effect of miR-378a inhibition on BL growth. The growth-promoting role might 
be related to regulation of one or multiple of the identified miR-378a-3p targets MNT, 
IRAK4, FOXP1, and JPX.  
Conclusions 
In conclusion, we identified 26 miRNAs differentially expressed between BL cells and 
GC-B cells and confirmed deregulated expression of 5 out of 8 miRNAs both in BL cell 
lines and tissue samples. For one of the differentially and highly abundant (top-10 in 
BL) miRNAs, miR-378a-3p, we showed a negative effect on BL cell growth upon 
inhibition and identified 4 novel target genes. By targeting these genes, i.e. IRAK4, 
MNT, FOXP1, and JPX, miR-378a may control BL cell growth.  
Materials and Methods  
BL cell lines, germinal center (GC) B cells, and BL patient material 
BL cell lines were purchased from ATCC (ST486 and Ramos) and DSMZ (CA46 and 
DG75). BL cells were cultured at 37°C under an atmosphere containing 5% CO2 in 
RPMI-1640 medium (Cambrex Biosciences, Walkersville, MD, USA) supplemented 
with 2nM ultra glutamine, 100U/ml penicillin, 0.1mg/ml streptomycin and 10% (CA46, 
DG75, and Ramos) or 20% (ST486) Fetal Bovine Serum (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). P493-6 B-cells were cultured as described previously [65]. We 
routinely confirmed cell line identity using the PowerPlex® 16HS System (Promega, 
Leiden, The Netherlands) and absence of mycoplasma contamination.  
GC-B cells and frozen BL tissue sections were obtained previously as described in 
[9,65,66]. GC-B cells (defined as CD20+IgD-CD38+, n=6 or IgD-CD138-CD3-CD10+, 
n=1) were sorted from routinely removed tonsil specimens of children. Specifically, for 
small RNA seq experiments FACS sorted (CD20+IgD-CD38+, n=2) and MACS sorted 
(IgD-CD138-CD3-CD10+, n=1) GC-B cells were used as controls, while FACS sorted 
(CD20+IgD-CD38+, n=4) GC-B cells were used for qRT-PCR validation experiments. 
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Written permissions for the use of the tonsil tissues to isolate GC-B cells were 
obtained from the parents of the children. The procedures followed for the BL tissue 
samples were according to the guidelines of the medical ethics board of the University 
Medical Center Groningen.  
RNA isolation 
RNA was isolated using miRNeasy Mini or Micro kit (Qiagen, Hiden, Germany) 
according to the manufacturer’s instructions. RNA concentration was measured by a 
NanoDropTM 1000 Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, USA) 
and integrity was evaluated on a 1% agarose gel.  
Small RNA library preparation and sequencing 
1-2 µg total RNA from 4 BL cell lines and 3 samples of GC-B cells was used to 
generate small RNA libraries using Truseq Small RNA Sample Preparation Kit and 
TruSeq small RNA indices (Illumina, San Diego, CA, USA). Sequencing was 
performed on an Illumina 2000 HiSeq platform. After removal of 3’- and 5’-adaptor 
sequences from the raw reads using the CLC Genomics Workbench (CLC bio, 
Cambridge, MA, USA), sequencing data were analyzed using miRDeep version 2.0 
(Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 
https://www.mdc-berlin.de/8551903/en) [67] and annotated against miRbase version 
21 (http://www.mirbase.org) [68] allowing one nucleotide mismatch. Read counts of 
miRNAs with the same mature miRNA sequence were merged. Total read counts per 
sample were normalized to 1,000,000. For statistical analysis, we included all unique 
miRNAs with at least 50 read counts in all seven samples. Genesis software v1.7.6 
(Institute for Genomics and Bioinformatic Graz, Graz, Austria) was used to generate 
the heat map. The small RNA sequencing data were deposited in the Gene 
Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo; accession number 
GSE92616). 
qRT-PCR 
For validation of small RNA sequencing results, we selected differentially expressed 
miRNAs with expression log2 RPM > 8 in BL or GC-B cells. We selected the most 
optimal Taqman assay based on isoform abundance as observed in the small RNA 
sequencing data (Table S2). The miRNA expression levels were analyzed using 
Taqman miRNA quantitative PCR assays (Thermo Fisher Scientific Inc.) in a 
multiplexed fashion as described previously [69]. Cycle crossing point (Cp) values 
were determined with Light Cycler 480 software version 1.5.0 (Roche, Basel, 
Switzerland). Relative expression levels of miRNAs to house-keeping gene (RNU44 
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or RNU49) were determined by calculating 2−△Cp (△Cp = CpmiRNA-Cphouse-keeping gene). 
MYC transcript levels were analyzed as indicated previously [65]. 
Lentiviral constructs, transduction and GFP competition assay 
Lentiviral constructs to inhibit (mZip-378a-3p) or overexpress (pCDH-miR-378a) 
miR-378a-3p were purchased from System Biosciences (Palo Alto, CA, USA). A 
non-targeting mZip-scrambled (SCR) and an empty vector pCDH (EV) construct were 
used as negative controls. Lentiviral particles were produced in HEK-293T cells by 
calcium phosphate precipitation transfection using a third-generation packaging 
system as described previously [66]. Briefly, HEK-293T cells were seeded in 6-well 
plates and grown till ~80% confluence. A plasmid mix consisting of 15μl CaCl2 (2.5M), 
1μg pMSCV-VSV-G, 1μg pRSV.REV, 1μg pMDL-gPRRE, 2μg lentiviral vector, and 
150μl of 2xHBS was prepared to transfect the HEK-293T cells. Virus was harvested 
and filtered by a 0.45μm filter 48 hours after transfection. Virus was either used 
directly or stored at -80°C. 
For GFP competition assays, BL cell lines were infected with the mZip-378a-3p and 
the negative control mZip-SCR in three biological replicates per construct, aiming at 
an infection efficiency of 20% to 50% GFP+ cells on day 4. The percentage of GFP+ 
cells was monitored by flow cytometry (BD Biosciences, San Jose, CA, USA) three 
times per week for a total period of 22 days.  
Ago2-IP procedure 
Immunoprecipitation (IP) of the Ago2-containing RISC (Ago2-IP) procedure was done 
as described previously [70]. To identify miR-378a-3p target genes we applied 
Ago2-RIP-Chip on BL cells infected with lentiviral miR-378a-3p inhibition or 
overexpression constructs. For both constructs a parallel infection with appropriate 
control constructs (non-targeting or empty vector) was performed. We aimed at a high 
infection percentage and harvested the cells at day 5, either directly or after sorting to 
reach a GFP+ percentage > 95% for inhibition and > 85% for overexpression. For 
each AGO2-IP experiment we started with ~30 million cells. RNA was isolated from 
the Ago2-IP and total (T) fractions. Efficiency of the Ago2-IP procedure was confirmed 
by qRT-PCR for miR-378a-3p and miR-181a and by western blot for the Ago2 protein.  
Western blotting 
Infected cells were harvested and lysed in lysis buffer (#9803, Cell Signaling 
Technology, Danvers, Massachusetts, USA) supplemented with protease inhibitor. 
After centrifugation at 14,000 rpm for 10 minutes (4°C), supernatants were collected, 
and protein concentrations were measured using the BCA Protein Assay Kit (Thermo 
Fisher Scientific Inc.) according to the manufacturer’s protocol. 20 µg protein was 
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separated on a polyacrylamide gel and transferred to a nitrocellulose membrane, 
followed by incubation overnight at 4°C with primary antibodies diluted in 5% milk in 
Tris-buffered saline with Tween-20 (TBST) and anti-Ago2 (1000x diluted, 2E12-1C9, 
Abnova, Taipei, Taiwan). After incubation with the secondary antibody and ECL 
substrate (Thermo Fisher Scientific Inc.), chemiluminescence was detected with 
ChemiDoc MP Scanner and proteins were visualized and quantified with Image Lab 
4.0.1 software (BioRad Hercules, CA, USA).  
Microarray analysis 
About 50 ng RNA of both the total (T) and the IP fractions were labeled and hybridized 
on an Agilent gene expression microarray (AMADID no.: 072363, SurePrint G3 
Human Gene Exp v3 array kit, Agilent Technologies). The microarray contained 
58,341 probes against coding and noncoding transcripts. The procedure and data 
analysis were performed as previously described [65]. Briefly, after cRNA synthesis 
and amplification, labeling was done with Cyanine 3-CTP (Cy3) or Cyanine 5-CTP 
(Cy5) using the LowInput QuickAmp Labeling kit (catalog no.: 0006322867). Equal 
amounts of Cy3- or Cy5-labeled cRNA samples were mixed and hybridized on the 
microarray slide overnight. Raw data were quantile normalized without baseline 
transformation using GeneSpring GX 12.5 software (Agilent Technologies). Probes 
were selected for further analysis if they were flagged present in all samples, 
expressed in the 25th to 100th percentile in at least half of the total (T) fractions, and 
showed consistent expression in the duplicate measurements (< 2-fold change). The 
average signals of replicates were used to calculate the IP/T ratio and probes with a ≥ 
2-fold enrichment in the IP fraction as compared to total (T) fraction were considered 
as potential miRNA targets.  
For pCDH-378a transduced cells, we next assessed miR-378a-3p targets by 
identifying probes that were enriched at least ≥ 2-fold higher in miR-378a 
overexpressing cells as compared to empty vector (pCDH-EV). For mZip-378a-3p 
transduced cells we assessed miR-378a-3p targets by identifying probes with at least 
≥ 2-fold higher enrichment in mZip-SCR transduced cells as compared to 
mZip-378a-3p cells. Gene expression microarray data are deposited in the Gene 
Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo; accession number 
will follow soon). 
Identification of miR-378a-3p seed sites and gene ontology (GO) 
terms 
For all Ago2-RIP-Chip identified targets of miR-378a-3p, we used a Pearl script to 
search for 7mer-A1, 7mer-m8, and 8mer [71] miR-378a-3p seed sites in 5’-UTR, CDS, 
and 3’-UTR. Ensemble transcript isoforms were selected based on a refseq ID 
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conversion using Biomart (https://www.ensembl.org/biomart). For lncRNA transcripts 
without an Ensembl ID, we used the LNCipedia or a XLOC/TCONS (BROAD institute) 
transcript ID. The growth-related gene ontology (GO) terms (proliferation, cell cycle, 
and apoptosis) for selected genes were retrieved from the Ensembl database 
(https://www.ensembl.org/biomart). 
Cloning of miRNA binding sites and luciferase reporter assay 
We adapted the psi-Check-2 vector (Promega, Madison, WI, USA) to remove the 
predicted miR-378a-3p target site (7mer-A1) in the open reading frame of the Renilla 
luciferase gene. The binding site was mutated by changing two nucleotides in the 
seed region without affecting the amino acid sequence. This was accomplished by 
substituting the 460nt long fragment between the EcoRV and XhoI sites of the 
psi-Check-2 vector (Figure S6, Integrated DNA technologies, Leuven, Belgium). 
Effective Renilla luciferase production independent of miR-378a-3p levels was 
confirmed (data not shown) before cloning putative binding sites of target genes.  
Ten potential miRNA binding sites of 8 miR-378a-3p target genes were ordered as 
58-mer oligo duplexes (Integrated DNA technologies) and cloned into the XhoI and 
NotI restriction sites of the modified luciferase reporter vector (Table S3). For the 
binding sites with a positive result in the first luciferase reporter assay, mutant controls 
were generated by cloning oligo duplexes with mutations in 3 nucleotides in the seed 
region. The reporter vectors with miR-378a-3p wild type or mutated binding sites were 
co-transfected with 10 µM of either miR-378a pre-miRNA (Cat. NO.: AM17100, 
Ambion) or control oligos (Cat. NO.: AM17111, Ambion) to ST486 and DG75 cells 
using an Amaxa nucleofector device (program A23) and the Amaxa Cell Line 
Nucleofector Kit V (Cat NO.: VACA-1003) (Amaxa, Gaithersburg, MD). Cells were 
harvested 24h after transfection. Renilla and Firefly luciferase activity in cell lysates 
were measured using a Dual-Luciferase Reporter Assay System (Promega). Each 
experiment was measured in duplicate and results were averaged per experiment. 
For each construct the luciferase assay was performed in three independent 
biological replicates.  
Statistical analysis 
MiRNAs significantly differentially expressed in the small RNA-seq profiling were 
identified with a moderated T-test and Benjamini-Hochberg correction for multiple 
testing using the GeneSpring GX software (version 12.5, Agilent Technologies Santa 
Clara, CA, USA). For confirmation of differentially expressed miRNAs by qRT-PCR, 
we used the nonparametric MannWhitney U-test (GraphPad Software Inc., San Diego, 
CA). Statistical analysis of GFP competition assays was performed as described 
previously [66]. Briefly, the percentage of mZip-378a-3p infected cells at day 4 was set 
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to 100% and were compared to percentages in the control over time using a mixed 
model with time and the interaction of time and miRNA construct type as fixed effect 
and measurement repeat within miRNA construct type as random effect in SPSS 
(22.0.0.0 version, IBM, Armonk, New York, USA). For the luciferase reporter assay, 
significance was calculated based on the Renilla to Firefly (RL/FL) luciferase ratios 
between experimental samples and negative controls using paired t-test (GraphPad 
Software Inc.).  
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Supplementary Figures 
 
Figure S1. Results of qRT-PCR validation experiments of the differential expression patterns 
observed by small RNA-seq in BL cell lines relative to germinal center B cells. The decreased 
levels of miR-28-3p and miR-30a-5p in BL cell lines relative to GC-B cells could not be validated by 
qRT-PCR. miRNA levels were normalized to RNU44.  
 
Figure S2. MiR-378a-3p levels in BL and germinal center B cells based on small RNA-seq data. 
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BL cell lines (black bars) and germinal center B-cells (GC-B, white bars). RPM=reads per million. 
 
Figure S3. Validation of Ago2-IP procedure in ST486 cells upon inhibition and overexpression of 
miR-378a-3p. Infection efficiency for (A) miR-378a-3p inhibition and (B) overexpression constructs in 
ST486. Enrichment of (C) miR-378a-3p and (D) a randomly selected control miRNA, miR-181a-5p in 
the Ago2 immunoprecipitated (IP) fraction in comparison to the total (T) fraction. (E) Western blot 
results of Ago2 protein in T, flow through (FT), and IP samples using the anti-Ago2 antibody or the 
control anti-IgG antibody for immunoprecipitation. 




Figure S4. Uncropped western blot results for Ago2 protein. WB results of total (T), flow through 
(FT), and Ago2-immunoprecipitation (IP) fractions for ST486 cells using the anti-Ago2 antibody or the 
control anti-IgG antibody upon miR-378a-3p inhibition (A) and overexpression (B) experiments (see 










Figure S5. Results of the luciferase reporter assays for 10 putative miR-378a-3p binding sites 
identified in 8 Ago-2 IP enriched genes. (A) results of ST486 and (B) DG75 cells. The 10 binding 
sites were cloned to the Psi-check-2 vector and co-transfected with miR-378a-3p mimics or negative 
control mimics to ST486 and DG75 BL cells. Binding of miR-378a-3p was confirmed for IRAK4, JPX, 
FOXP1-site1 and MNT in both cell lines. 
 
Figure S6. Sequence of the minigene used to generate a luciferase reporter vector without the 
putative miR-378a-3p binding site in the Renilla gene. The miR-378a seed sequence in shown in 























Table S1. Small RNA sequencing read summary 
Sample 
Total after trimming Mapping to Human genome Mapping to miRbase 21 
Reads Collapsed Reads Percentage Collapsed Reads Percentage Collapsed 
ST486 12,728,371 679,193 9,215,947 72.4% 477,577 7,951,451 62.5% 19,074 
CA46 17,810,149 193,500 15,429,749 86.6% 45,386 13,035,709 73.2% 17,595 
DG75 5,553,807 295,796 4,542,877 81.8% 192,986 3,267,634 58.8% 16,337 
Ramos 9,001,167 566,396 6,671,654 74.1% 390,175 4,040,003 44.9% 14,824 
GC-1 9,234,697 357,071 6,993,299 75.7% 176,567 5,541,436 60.0% 15,998 
GC-2 9,637,128 620,514 5,225,051 54.2% 389,723 2,534,968 26.3% 13,262 
GC-3 6,758,291 524,000 4,660,685 69.0% 284,438 3,563,084 52.7% 15,879 
Table S2. Taqman miRNA assays used for qRT-PCR validation 
No. miRNA Catalog No.                   Sequence 
1 miR-378a-3p 2243 5’-ACUGGACUUGGAGUCAGAAGG-3’ 
2 miR-28-5p 0411 5’-AAGGAGCUCACAGUCUAUUGAG-3’ 
3 miR-155-5p 2623 5’-UUAAUGCUAAUCGUGAUAGGGGU-3’ 
4 miR-363-3p 1271 5’-AAUUGCACGGUAUCCAUCUGUA-3’ 
5 miR-222-3p 2276 5’-AGCUACAUCUGGCUACUGGGU-3’ 
6 miR-221-3p 1134 5’-AGCUACAUUGUCUGCUGGGUUU-3’ 
7 miR-30a-5p 0417 5’-UGUAAACAUCCUCGACUGGAAG-3’ 
















Chapter 3   
86 
 
Table S3. Oligos for cloning miR-378a-3p binding sites from selected genes, wild type 
and with mutations in miR-378a-3p seed.  









IRAK4-MBS-S TCGAAATCTTGAACAAAGCTATATGCCACCTGACTCCTCAAGTCCAGAAAATAAAAGT  
IRAK4-MBS-AS GGCCACTTTTATTTTCTGGACTTGAGGAGTCAGGTGGCATATAGCTTTGTTCAAGATT 
IRAK4-MBS-mut-S TCGAAATCTTGAACAAAGCTATATGCCACCTGACTCCTCAACTGCTGAAAATAAAAGT  
IRAK4-MBS-mut-AS GGCCACTTTTATTTTCAGCAGTTGAGGAGTCAGGTGGCATATAGCTTTGTTCAAGATT 
3 JPX 
JPX-MBS-S TCGAGTTGCAAGGCGTCCGAAGTATGAGTCCACTAACAAAAGTCCAGAAACTCGCCAGT  
JPX-MBS-AS GGCCACTGGCGAGTTTCTGGACTTTTGTTAGTGGACTCATACTTCGGACGCCTTGCAAC  








BCR-site1-MBS-S TCGAGGCCACCTGAGGGCGCCCCAAGCCAGTTCATCTCGGAGTCCAGGCCTGGCCCTG  










TUBA1C-MBS-S TCGACGTGAGTGCATCTCCATCCACGTTGGCCAGGCTGGTGTCCAGATTGGCAATGCC  
TUBA1C-MBS-AS GGCCGGCATTGCCAATCTGGACACCAGCCTGGCCAACGTGGATGGAGATGCACTCACG  
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